Neurotoxicity Research

, Volume 32, Issue 2, pp 291–300 | Cite as

Long-Term Abobotulinumtoxin A Treatment of Cervical Dystonia

  • A. R. Bentivoglio
  • E. Di Stasio
  • D. Mulas
  • M. L. Cerbarano
  • T. Ialongo
  • A. Laurienzo
  • Martina Petracca


Botulinum toxin is considered as first-line therapy for cervical dystonia, but few papers have addressed these issues in the long term. Aim of this study was to investigate the long-term efficacy and safety of abobotulinumtoxin A (A/Abo) in patients with primary cervical dystonia. Consecutive patients who received at least six injections with A/Abo were included. Safety was assessed on patients’ self-reports. Efficacy was assessed by recording the total duration of benefit, duration of maximum efficacy, disease severity measured by means of the Tsui score, and pain intensity evaluated by means of the visual analog scale (VAS). Thirty-nine patients with PCD were included. The mean dose injected was 701.5 ± 280.6 U. The mean duration of the clinical improvement was 93.0 ± 30.7 days, while the mean duration of the maximum clinical improvement was 77.1 ± 27.1 days. The mean VAS before and 4 weeks after injection was 4.4 ± 1.8 and 1.8 ± 1.6, respectively. The mean Tsui score before and 4 weeks after treatment was 5.7 ± 1.8 and 3.5 ± 1.5, respectively. Doses of A/Abo and duration of the maximum clinical improvement significantly increased over time, while the Tsui score and VAS displayed a tendency to decrease along time. Side effects occurred in 19.6% of all the treatments but were severe in only four injections. The results of our study confirm the effectiveness and safety profile of A/Abo for the long-term treatment of primary cervical dystonia.


Cervical dystonia Botulinum toxin Long-term treatment abobotulinumtoxinA 







botulinum toxin


cervical dystonia


clinical global assessment


deep brain stimulation


dopamine receptor blocking agents






primary cervical dystonia


standard deviation




Statistical Package for Social Sciences


Visual analog scale.


  1. Albanese A, Asmus F, Bhatia KP et al (2011) EFNS guidelines on diagnosis and treatment of primary dystonias. Eur J Neurol 18:5–18CrossRefPubMedGoogle Scholar
  2. Aoki KR (2003) Evidence for antinociceptive activity of botulinum toxin type a in pain management. Headache 43(Suppl 1):S9–15CrossRefPubMedGoogle Scholar
  3. Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A (2009a) Outcome predictors, efficacy and safety of Botox and Dysport in the long-term treatment of hemifacial spasm. Eur J Neurol Mar 16(3):392–398. doi:10.1111/j.1468-1331.2008.02507.x CrossRefGoogle Scholar
  4. Bentivoglio AR, Fasano A, Ialongo T, Soleti F, Lo Fermo S, Albanese A (2009b) Fifteen-year experience in treating blepharospasm with Botox or Dysport: same toxin, two drugs. Neurotox Res 15(3):224–231. doi:10.1007/s12640-009-9023-3 CrossRefPubMedGoogle Scholar
  5. Bentivoglio AR, Ialongo T, Bove F, De Nigris F, Fasano A (2012) Retrospective evaluation of the dose equivalence of Botox(®) and Dysport (®) in the management of blepharospasm and hemifacial spasm: a novel paradigm for a never ending story. Neurol Sci 33(2):261–267. doi:10.1007/s10072-011-0672-7 CrossRefPubMedGoogle Scholar
  6. Buchman AS, Comella CL, Stebbins GT, Tanner CM, Goetz CG (1993) Quantitative electromyographic analysis of changes in muscle activity following botulinum toxin therapy for cervical dystonia. Clin Neuropharmacol 16:205–210CrossRefPubMedGoogle Scholar
  7. Camargo CH, Teive HA, Becker N, Baran MH, Scola RH, Werneck LC (2008) Cervical dystonia: clinical and therapeutic features in 85 patients. Arq Neuropsiquiatr 66:15–21CrossRefPubMedGoogle Scholar
  8. Camargo CH, Teive HA, Becker N, Munhoz RP, Werneck LC (2011) Botulinum toxin type a and cervical dystonia: a seven-year follow-up. Arq Neuropsiquiatr 69(5):745–750CrossRefPubMedGoogle Scholar
  9. Camfield L, Ben-Shlomo Y, Warner TT (2002) Epidemiological study of dystonia in Europe Collaborative group. Impact of cervical dystonia on quality of life. Mov Disord 17(4):838–841CrossRefPubMedGoogle Scholar
  10. Carruthers A, Carruthers J (2007) Eyebrow height after botulinum toxin type A to the glabella. Dermatol Surg 33(1 Spec No.):S26–31Google Scholar
  11. Chan J, Brin MF, Fahn S (1991) Idiopatic cervical dystonia: clinical characteristics. Mov Disord 6:119–126CrossRefPubMedGoogle Scholar
  12. Charles PD, Manack Adams A, Davis T, Bradley K, Schwartz M, Brin MF, Patel AT (2016) Neck pain and cervical dystonia: treatment outcomes from CD PROBE (cervical dystonia patient registry for observation of OnabotulinumtoxinA efficacy). Pain Pract 16(8):1073–1082Google Scholar
  13. Colosimo C, Suppa A, Fabbrini G, Bologna M, Berardelli A (2010) Craniocervical dystonia: clinical and pathophysiological features. Eur J Neurol 17(Suppl 1):15–21. doi:10.1111/j.1468-1331.2010.03045.x CrossRefPubMedGoogle Scholar
  14. Colosimo C, Tiple D, Berardelli A (2012) Efficacy and safety of long-term botulinum toxin treatment in craniocervical dystonia: a systematic review. Neurotox Res 22(4):265–273. doi:10.1007/s12640-012-9314-y CrossRefPubMedGoogle Scholar
  15. Comella CL, Buchman AS, Tanner CM, Brown-Toms NC, Goetz CG (1992) Botulinum toxin injection for spasmodic torticollis: increased magnitude of benefit with electromyographic assistance. Neurology 42(4):878–882CrossRefPubMedGoogle Scholar
  16. Cui M, Khanijou S, Rubino J, Aoki KR (2004) Subcutaneous administration of botulinum toxin a reduces formalin-induced pain. Pain 107(1–2):125–133CrossRefPubMedGoogle Scholar
  17. Dauer WT, Burke RE, Greene P, Fahn S (1998) Current concepts on the clinical features, aetiology and management of idiopathic cervical dystonia. Brain 121(Pt 4):547–560CrossRefPubMedGoogle Scholar
  18. Defazio G, Jankovic J, Giel JL, Papapetropoulos S (2013) Descriptive epidemiology of cervical dystonia. Tremor Other Hyperkinet Mov (N Y) 4:3Google Scholar
  19. Dressler D (2000) Electromyographic evaluation of cervical dystonia for planning of botulinum toxin therapy. Eur J Neurol 7:713–718CrossRefPubMedGoogle Scholar
  20. Dressler D, Paus S, Seitzinger A, Gebhardt B, Kupsch A (2013) Long-term efficacy and safety of incobotulinumtoxinA injections in patients with cervical dystonia. J Neurol Neurosurg Psychiatry 84(9):1014–1019CrossRefPubMedPubMedCentralGoogle Scholar
  21. Epidemiologic Study of Dystonia in Europe (ESDE) Collaborative Group (1999) Sex-related influences on the frequency and age of onset of primary dystonia. Neurology 53(8):1871–1873CrossRefGoogle Scholar
  22. Filippi GM, Errico P, Santarelli R et al (1993) Botulinum a toxin effects on rat jaw muscle spindles. Acta Otolaryngol 113:400–404CrossRefPubMedGoogle Scholar
  23. Giglio F, Curra A, Lorenzano C, Modugno N, Manfredi M, Berardelli A (2000) Effects of botulinum toxin type a on intracortical inhibition in patients with dystonia. Ann Neurol 48:20–26CrossRefGoogle Scholar
  24. Gordon MF, Brashear A, Elovic E, Kassicieh D, Marciniak C, Liu J, Turkel C, BOTOX Poststroke Spasticity Study Group (2004) Repeated dosing of botulinum toxin type a for upper limb spasticity following stroke. Neurology 63(10):1971–1973CrossRefPubMedGoogle Scholar
  25. Haussermann P, Marczoch S, Klinger C, Landgrebe M, Conrad B, Ceballos-Baumann A (2004) Long-term follow-up of cervical dystonia patients treated with botulinum toxin a. Mov Disord 19:303–308CrossRefPubMedGoogle Scholar
  26. Hsiung G-YR, Das SK, Ranawaya R, Lafontaine A-L, Suchowersky O (2002) Long-term efficacy of botulinum toxin a in treatment of various movement disorders over a 10-year period. Mov Disord 17:1288–1293CrossRefPubMedGoogle Scholar
  27. Jahanshahi M, Marion MH, Marsden CD (1990) Natural history of adult-onset idiopathic torticollis. Arch Neurol 47:548–552CrossRefPubMedGoogle Scholar
  28. Jankovic J (2004) Treatment of cervical dystonia. In: Brin M, Comella CL, Jankovic J (eds) Dystonia etiology, clinical features, and treatment. Lippincott Williams & Wilkins, Philadelphia, pp 159–166Google Scholar
  29. Jankovic J (2006) Botulinum toxin therapy for cervical dystonia. Neurotox Res 9(2–3):145–148CrossRefPubMedGoogle Scholar
  30. Jankovic J, Orman J (1987) Botulinum A toxin for cranial-cervical dystonia. Neurology 37:616–623. doi:10.1212/WNL.37.4.616 CrossRefPubMedGoogle Scholar
  31. Jankovic J, Tsui J, Bergeron C (2007) Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord 13(7):411–416CrossRefPubMedGoogle Scholar
  32. Jankovic J, Adler CH, Charles D, Comella C et al (2015) Primary results from the cervical dystonia patient registry for observation of OnabotulinumtoxinA efficacy (CD PROBE). J Neurol Sci 349(1–2):84–93CrossRefPubMedGoogle Scholar
  33. Kutvonen O, Dastidar P, Nurmikko T (1997) Pain in spasmodic torticollis. Pain 69:279–286CrossRefPubMedGoogle Scholar
  34. Maia FM, Kanashiro AK, Chien HF, Goncalves LR, Barbosa ER (2010) Clinical changes of cervical dystonia pattern in long-term botulinum toxin treated patients. Parkinsonism Relat Disord 16:8–11CrossRefPubMedGoogle Scholar
  35. Mejia NI, Young KD, Jankovic J (2005) Long-term botulinum toxin efficacy, safety and immunogenicity. Mov Disord 20:592–597CrossRefPubMedGoogle Scholar
  36. Mohammadi B, Buhr N, Bigalke H, Krampfl K, Dengler R, Kollewe K (2009) A long-term follow-up of botulinum toxin a in cervical dystonia. Neurol Res 31:463–466 12 CrossRefPubMedGoogle Scholar
  37. Molho E, Jankovic J, Lew M (2008) Role of botulinum toxin in the treatment of cervical dystonia. Neurol Clin 26:43–53CrossRefPubMedGoogle Scholar
  38. Naumann M, Jankovic J (2004) Safety of botulinum toxin type a: a systematic review and meta-analysis. Curr Med Res Opin 20(7):981–990CrossRefPubMedGoogle Scholar
  39. Palomar FJ, Mir P (2012) Neurophysiological changes after intramuscular injection of botulinum toxin. Clin Neurophysiol 123:54–60CrossRefPubMedGoogle Scholar
  40. Poewe W, Deuschl G, Nebe A, Feifel E, Wissel J, Benecke R, KR Kessler, Ceballos-Baumann AO, Ohly A, Oertel W, Kunig G (1998) What is the optimal dose of botulinum toxin A in the treatment of cervical dystonia? Results of a double blind, placebo controlled, dose ranging study using DysportÂ. J Neurol Neurosurg Psychiatry 64(1):13–17Google Scholar
  41. Ramirez-Castaneda J, Jankovic J (2013) Long-term efficacy and safety of botulinum toxin injections in dystonia. Toxins (Basel) 5(2):249–266CrossRefGoogle Scholar
  42. Ramirez-Castaneda J, Jankovic J (2014) Long-term efficacy, safety, and side effect profile of botulinum toxin in dystonia: a 20-year follow-up. Toxicon 90:344–348CrossRefPubMedGoogle Scholar
  43. Rosales RL, Dressler D (2010) On muscle spindles, dystonia and botulinum toxin. Eur J Neurol 17:71–80CrossRefPubMedGoogle Scholar
  44. Simpson DM, Blitzer A, Brashear A et al (2008) Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the therapeutics and technology assessment Subcommittee of the American Academy of Neurology. Neurology 70:1699–1706CrossRefPubMedGoogle Scholar
  45. Simpson DM, Hallett M, Ashman EJ et al (2016) Practice guideline update summary: botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache: report of the guideline development Subcommittee of the American Academy of Neurology. Neurology 86(19):1818–1826. doi:10.1212/WNL.0000000000002560 CrossRefPubMedPubMedCentralGoogle Scholar
  46. Skogseid IM, Kerty E (2005) The course of cervical dystonia and patient satisfaction with long-term botulinum toxin a treatment. Eur J Neurol 12:163–170CrossRefPubMedGoogle Scholar
  47. Stacy M (2008) Epidemiology, clinical presentation, and diagnosis of cervical dystonia. Neurol Clin 26(Suppl 1):23–42CrossRefPubMedGoogle Scholar
  48. Tarsy D, Simon DK (2006) Dystonia. N Engl J Med 355(8):818–829CrossRefPubMedGoogle Scholar
  49. Truong D, Duane DD, Jankovic J et al (2005) Efficacy and safety of botulinum type a toxin (Dysport) in cervical dystonia: results of the first US randomized, double-blind, placebo-controlled study. Mov Disord 20:783–791CrossRefPubMedGoogle Scholar
  50. Truong D, Brodsky M, Lew M et al (2010) Long-term efficacy and safety of botulinum toxin type a (Dysport) in cervical dystonia. Parkinsonism Relat Disord 16(5):316–323CrossRefPubMedGoogle Scholar
  51. Tsui JK, Eisen A, Stoessl AJ, Calne S, Calne DB (1986) Double-Blind Study of Botulinum Toxin in Spasmodic Torticollis. Lancet 2, No.8501, pp. 245–247, ISSN 1474-547XGoogle Scholar
  52. Vivancos-Matellano F, Ybot-Gorrin I, Diez-Tejedor E (2012) A 17-year experience of abobotulinumtoxina in cervical dystonia. Int J Neurosci Jul 122(7):354–357. doi:10.3109/00207454.2012.665971 CrossRefGoogle Scholar
  53. Wissel J, Kanovsky P, Ruzicka E et al (2001) Efficacy and safety of a standardised 500 unit dose of Dysport (clostridium botulinum toxin type a haemaglutinin complex) in a heterogeneous cervical dystonia population: results of a prospective, multicentre, randomised, double-blind, placebo-controlled, parallel group study. J Neurol 248:1073–1078CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2017

Authors and Affiliations

  • A. R. Bentivoglio
    • 1
    • 2
  • E. Di Stasio
    • 3
  • D. Mulas
    • 1
  • M. L. Cerbarano
    • 1
  • T. Ialongo
    • 1
  • A. Laurienzo
    • 1
  • Martina Petracca
    • 1
  1. 1.Center for Parkinson Disease and Extrapyramidal Disorders, Movement Disorders Unit, Institute of NeurologyUniversità Cattolica del Sacro CuoreRomeItaly
  2. 2.Fondazione Don Carlo GnocchiMilanItaly
  3. 3.Institute of Biochemistry and Clinical BiochemistryUniversità Cattolica del Sacro CuoreRomeItaly

Personalised recommendations